Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Inclusion Criteria: * Pediatric patients with diagnosis of CD33 positive (\> 3%), * Newly diagnosed secondary AML * Relapsed refractory acute myeloid leukemia by World Health Organization (WHO) criteria Patients must have \>= 5% blasts in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with \>= 5% blasts in the peripheral blood * Pediatric Patients with myelodysplastic syndrome (MDS) who progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS * Performance status: Lansky \>= 50 for patients who are =\< 16 years old and Karnofsky \>= 50% for patients who are \> 16 years old * Age =\< 21 years of age * Total serum bilirubin =\< 2 x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to =\< 3 x ULN * Serum creatinine =\< 2.0 mg/dl * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =\< 3 x ULN; =\< 5 x ULN in case of suspected leukemic liver involvement * Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and for 30 days following the last dose of study drug. Effective methods of birth contro…